The ROS/RNS sensors showed favorable pharmacokinetics, localized in the myocardial infarction area in mice (Figure 14C) and the oxazine fluorescence was shown to coincide with the area rich in MPO, making the ROS/RNS nanosensor a promising technology to identify the sites of inflammation in atherosclerosis, cancer, metastasis and organ rejection.[136]. The gene discussed is MPO; the disease is cancer.